Newsroom
October 4, 2024
Simon Gayther, PhD, professor of medicine in the Division of Hematology and Oncology in the Joe R. and Teresa Lozano Long School of Medicine and founding director in the school’s Center for Inherited Oncogenesis at The University of Texas Health Science Center at San Antonio (UT Health San Antonio), received a $500,000 UT System […]
October 3, 2024
Winners will each receive a $10,000 cash prize During Primary Care Week, three students from the Joe R. and Teresa Lozano Long School of Medicine were named winners of the inaugural Carolyn Ann Bellue Holly Annual Student Essay Contest. The winners were chosen from four finalists who participated in a virtual panel discussion on Monday, […]
October 3, 2024
In the study of uncommon congenital disorders, collaboration is key to potential new insights and discoveries. The Gabriella Miller Kids First Pediatric Research Program Data Resource Center announced in September the public release of three comprehensive datasets related to childhood cancers and congenital disorders, one of which was provided by The University of Texas Health […]
October 3, 2024
Approximately 30% of individuals with myeloid malignancy diseases have a mutation in a certain gene called tet methylcytosine dioxygenase 2 (TET2). This gene is responsible for providing instructions on creating certain proteins and is known to have a tumor-suppressive function. A study published October 2 in Nature is the first to explain the pathway of […]
October 1, 2024
Pancreatic ductal adenocarcinoma (PDAC), a certain type of pancreatic cancer, is a ruthless killer with an average five-year survival rate of less than 10%. Most patients are diagnosed at a late stage when the cancer has already spread throughout their bodies. And the problem is only growing worse. By 2030, pancreatic cancer is expected […]
September 30, 2024
Charles P. France, PhD, to lead methocinnamox drug development program The University of Texas Health Science Center at San Antonio (UT Health San Antonio) was awarded a $12 million cooperative agreement (U01) from the National Institutes of Health’s National Institute on Drug Abuse to further develop methocinnamox (MCAM) as a treatment for opioid use disorder. […]